Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Doroshow Website

James H. Doroshow, M.D.

Portait Photo of James Doroshow
Developmental Therapeutics Branch
Head, Oxidative Signaling and Molecular Therapeutics Group
Adjunct Investigator
Center for Cancer Research
National Cancer Institute
Building 31, Room 3A44
Bethesda, MD 20892
Fax Number not listed


Dr. James H. Doroshow has been the Director of Division of Cancer Treatment and Diagnosis, National Cancer Institute, since 2004, and Deputy NCI Director for Clinical and Translational Research since 2011. From 1983 to 2004, Dr. Doroshow was the Chairman of the City of Hope Comprehensive Cancer Center's Department of Medical Oncology and Therapeutics Research. From the time of his first research grant in 1980, Dr. Doroshow was continuously funded by NCI until he moved to the NIH in 2004. He is the author of over 400 full-length publications in the areas of anthracycline antibiotic molecular pharmacology, the role of oxidant stress in tumor cell signal transduction, and novel therapeutic approaches to solid tumors. Dr. Doroshow served from 1995-2001 as a member of the Subspecialty Board on Medical Oncology of the American Board of Internal Medicine, from 1999-2000 as Chair of NCI's Scientific Review Group A-Cancer Centers, and from 2004-2007 as a member of the FDA's Oncologic Drugs Advisory Committee. He is currently the Chair of the NIH Clinical Trials Working group; a member of the Institute of Medicine's Forum on Drug Discovery, Development, and Translation; an Associate Editor of the 5th Edition of Abeloff's Clinical Oncology (2014); and the Oncology Editor of the 25th Edition of the Cecil Textbook of Medicine.

Dr. Doroshow received his bachelor's degree, magna cum laude, from Harvard College in 1969 and his medical degree from Harvard Medical School in 1973. After completing an internship and residency in Internal Medicine at the Massachusetts General Hospital in Boston, he spent three years (1975-78) performing his fellowship in Medical Oncology on the Medicine and Clinical Pharmacology Branches of the NCI.


Our laboratory focuses on the role of oxidant-mediated signalling in cytokine-, growth factor- and drug-related alterations of tumor cell proliferation. We are particularly interested in the epithelial NADPH oxidase gene family and the development of novel small molecular inhibitors of these proteins.

This page was last updated on 3/31/2014.